Clinical trial
A Phase 1/2 Study of N-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab
Name
CA-ALT-803-02-14
Description
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab.
Trial arms
Trial start
2015-04-17
Estimated PCD
2020-12-13
Trial end
2020-12-13
Status
Terminated
Phase
Early phase I
Treatment
Rituximab
Intravenous infusion 375 mg/m\^2.
Arms:
Phase 1 Cohort 1: N-803 - IV 1 ug/kg, Phase 1 Cohort 2: N-803 - IV 3 ug/kg, Phase 1 Cohort 3: N-803 - IV 6 ug/kg, Phase 1 Cohort 4: N-803 - SQ 6 ug/kg, Phase 1 Cohort 5: N-803 - SQ 10 ug/kg, Phase 1 Cohort 6: N-803 - SQ 15 ug/kg, Phase 1 Cohort 7: N-803 - SQ 20 ug/kg, Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg, Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg
Other names:
Rituxin
N-803
Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.
Arms:
Phase 1 Cohort 1: N-803 - IV 1 ug/kg, Phase 1 Cohort 2: N-803 - IV 3 ug/kg, Phase 1 Cohort 3: N-803 - IV 6 ug/kg, Phase 1 Cohort 4: N-803 - SQ 6 ug/kg, Phase 1 Cohort 5: N-803 - SQ 10 ug/kg, Phase 1 Cohort 6: N-803 - SQ 15 ug/kg, Phase 1 Cohort 7: N-803 - SQ 20 ug/kg, Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg, Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg
Size
43
Primary endpoint
MTD or MED of N-803: IV 1, 3, 6 μg/kg, SQ 6, 10, 15, 20 μg/kg
9 months
Number of Participants With Treatment Emergent Adverse Events
30 days after last dose, up to 40 weeks
Overall Response Rate
60 months
Eligibility criteria
DISEASE CHARACTERISTICS:
* Histologically confirmed diagnosis of iNHL (Follicular lymphoma grade 1, 2, 3a; marginal zone lymphoma; small lymphocytic lymphoma or lymphoplasmacytic lymphoma) after treatment with at least 1 or more prior rituximab-containing regimens.
* Anti-CD20 mAb-refractory disease is defined as progressive disease while on rituximab (or another treatment of an anti-CD20 monoclonal antibody) or progression within 6 months of rituximab-containing (or another treatment of an anti-CD20 antibody-containing) therapy.
* Anti-CD20 mAb-sensitive disease is defined by a response to a prior rituximab-containing (or another treatment of an anti-CD20 monoclonal antibody) regimen, and relapse more than 6 months from the last administration of rituximab-containing (or another treatment of an anti-CD20 antibody-containing) therapy.
* Measurable disease:
* At least one lymph node group ≥ 1.5 cm in longest transverse dimension. Patients with cutaneous only disease may be enrolled if they have a clearly measurable skin lesion.
* Relapsed or Refractory iNHL that has progressed during or following 1 or more prior systemic rituximab-containing (or another treatment of an anti-CD20 antibody-containing) regimens for lymphoma
PRIOR/CONCURRENT THERAPY:
* No anti-lymphoma treatments within 28 days before the start of study treatment.
* Must have recovered from side effects of prior treatments.
PATIENT CHARACTERISTICS:
Performance Status
• ECOG 0, 1, or 2
Renal Function • Glomerular Filtration Rate (GFR) \> 40mL/min or Serum creatinine ≤ 1.5 X ULN
Bone Marrow Reserve
* Platelets ≥30,000/uL
* Hemoglobin ≥ 8g/dL
* Absolute Lymphocytes ≥800/uL
* ANC/AGC ≥750/uL
Hepatic Function
* Total bilirubin ≤ 2.0 X ULN (unless Gilbert's Syndrome or disease infiltration of liver is present)
* AST, ALT ≤ 3.0 X ULN, or ≤ 5.0 X ULN (if liver lymphoma is present)
* No positive Hep C serology or active Hep B infection
Cardiovascular
* No congestive heart failure \< 6 months
* No unstable angina pectoris \< 6 months
* No myocardial infarction \< 6 months
* No history of ventricular arrhythmias or severe cardiac dysfunction
* No history of uncontrollable supraventricular arrhythmias
* No NYHA Class \> II CHF
* No marked baseline prolongation of QT/QTc interval
Pulmonary
• Normal clinical assessment of pulmonary function
Other
* Negative serum pregnancy test if female and of childbearing potential
* Women who are not pregnant or nursing
* Subjects, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study
* No known autoimmune disease other than corrected hypothyroidism
* No known prior organ allograft or allogeneic transplantation
* Not HIV positive
* No active CNS involvement with lymphoma
* No psychiatric illness/social situation that would limit compliance
* No other illness that in the opinion of the investigator would exclude the subject from participating in the study
* Must provide informed consent and HIPPA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations
* No active systemic infection requiring parenteral antibiotic therapy
* No disease requiring systemic immunosuppressive therapy (inhaled or topical steroids are allowed). Adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
* No known histologic transformation from iNHL to DLBCL
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 43, 'type': 'ACTUAL'}}
Updated at
2024-07-03
1 organization
2 drugs
1 indication
Organization
Altor BioScienceDrug
VarlilumabIndication
Indolent B Cell Non-Hodgkin LymphomaDrug
N-803